RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) today announced that the Company had been awarded $1.1 million in grants under the U.S. Government’s Qualifying Therapeutic Discovery Project (QTDP) program to advance the development of the Company’s clinical programs for peramivir, BCX4208 and forodesine, as well as the pre-clinical BCX4161 kallikrein inhibitor and JAK inhibitor programs.
